ArticleNature2024
RNA m
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.Leukemia · 2026Trial
- Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis.Cancer cell · 2026Article
- A One-Step Chemoselective Strategy for Hydroxymethylcytosine Sequencing in DNA and RNA.bioRxiv : the preprint server for biology · 2026Article
- How Epitranscriptomic Machinery Senses Environmental Cues.Advanced biology · 2026Review
- Rewiring of de novo serine synthesis supports tumorigenesis under deficiency of TET2.British journal of cancer · 2026Article
- Beyond mBiomedicines · 2026Review
- Mechanistic Study of m5C Modification in Stem Cell Differentiation and Disease Regulation.Stem cell reviews and reports · 2026Review
- Tumor cell-intrinsic TET3 restrains type I interferon signaling and anti-tumor immunity.Science China. Life sciences · 2026Article
- RNA modifications as innovative pharmaceutical targets: emerging drug delivery strategies and precision therapeutics for cancer immunotherapy and metabolic diseases.Molecular biology reports · 2026Review
- Ten-eleven translocation 2-mediated DNA demethylation plays a positive regulatory role in BMP9-induced osteogenic differentiation of mesenchymal stem cells.Genes & diseases · 2026Article
- Substrate selectivity of the human RNA mNature · 2026Article
- Role of RNA 5‑methylcytosine modification in cancer: Insights from coding and non‑coding RNAs (Review).Molecular medicine reports · 2026Review
- TAF15-mediated m5C modification of MTHFD2 RNA reveals a novel therapeutic target for IDH mutant gliomas.Biomarker research · 2026Article
- IDMME and IDMDE: inducible CRISPR-dCasRx platforms for spatiotemporal RNA mGenome biology · 2026Article
- RNA modifications and epigenetic regulation in plants.aBIOTECH · 2026Review
- Regulatory elements on chromatin-associated RNA 15 years beyond RNA epigenetics.Nature chemical biology · 2026Review
- Epitranscriptomic control of cancer: the emerging roles of m⁵C and ac⁴C RNA modifications.Cell death discovery · 2026Review
- RNA modifications in cancer and their detection: a review.Japanese journal of clinical oncology · 2026Review
- RNA-m5C regulatory atlas of human fetal tissues uncover the activities of Nsun2/Jarid2/Alyref axis.Journal of advanced research · 2026Article
- Emerging roles of non-mNature plants · 2026Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Zhongyu Zou *Department of Chemistry, The University of Chicago, Chicago, IL, USA.ORCID 0000-0001-7152-5435
Xiaoyang Dou *Department of Chemistry, The University of Chicago, Chicago, IL, USA.
Ying Li *Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0002-3308-906X
Zijie ZhangDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-4900-506X
Juan WangDepartment of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Boyang GaoHoward Hughes Medical Institute, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-6956-1450
Yu XiaoDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.
Yiding WangHoward Hughes Medical Institute, The University of Chicago, Chicago, IL, USA.
Lijie ZhaoDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.
Chenxi SunDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.ORCID 0009-0000-7849-976X
Qinzhe LiuDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.
Xianbin YuDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.
Hao WangDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.
Juyeong HongDepartment of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Qing DaiDepartment of Chemistry, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-8578-1568
Feng-Chun YangDepartment of Cell Systems and Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0001-8524-4095
Mingjiang XuDepartment of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. xum1@uthscsa.edu.ORCID 0000-0002-7063-6253
Chuan HeDepartment of Chemistry, The University of Chicago, Chicago, IL, USA. chuanhe@uchicago.edu.ORCID 0000-0003-4319-7424
Funding
Transcriptome-wide base-resolution sequencing of pseudouridine in human normal and AD brain tissues-CEGS Admin supplement 2020-2021RM1HG008935 · NHGRI · UNIVERSITY OF CHICAGO · PI HE, CHUAN · 2016 to 2025
$24.4MTherapeutic value and mechanistic action of PSPC1 in AMLR01CA285299 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jianlong Wang, Mingjiang Xu · 2024 to 2026
$3.0MRoles of TET2-dependent DNA demethylation intermediates in hematological malignanciesR01HL145883 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI XU, MINGJIANG, YANG, FENG-CHUN · 2019 to 2022
$2.2MCritical roles of RNA m5C-MBD6-H2AK119ub deubiquitylation axis in TET2-mediated HSC regulationR01HL174477 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHUAN HE, Mingjiang Xu · 2024 to 2026
$2.1MTET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesisR01HL146664 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI WANG, JIANLONG, XU, MINGJIANG · 2019 to 2022
$1.7MNCI NIH HHS R01 CA285299NHGRI NIH HHS RM1 HG008935NHLBI NIH HHS R01 HL145883NHLBI NIH HHS R01 HL146664NHLBI NIH HHS R01 HL174477
Abstract
Mutation of tet methylcytosine dioxygenase 2 (encoded by TET2) drives myeloid malignancy initiation and progression
Indexed as
5-MethylcytosineCarcinogenesisChromatinDioxygenasesDNA-Binding ProteinsLeukemiaRNAAnimalsCell ProliferationCell Self RenewalFemaleHematopoiesisHistonesHumansMaleMice5-MethylcytosineChromatinDioxygenasesDNA-Binding ProteinsHistonesMBD6 protein, humanRetroelementsRNATET2 protein, humanTet2 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.